Julie fox
Has grant
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
Recent Grants
Grant: Close
The immunogenicity of Shingrix vaccination in HIV infected groups at risk of shingles infection (SAGE)
Open Date: 2022-09-01
Close Date: 2025-09-01
Grant: Close
COVID-19 Antibody Repertoires in Infection and Vaccination (COVAB- B)
Open Date: 2021-09-01
Close Date: 2023-09-01
Grant: Close
Investigating COVID-19 infectiousness and antibody evolution in COVID-19 patients in Africa and Europe
Open Date: 2020-09-01
Close Date: 2022-09-01
Grant: Close
The RIO Trial: A randomised placebo controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo in treated Primary HIV Infection on viral control off ART
Open Date: 2020-03-01
Close Date: 2025-03-01
Grant: Close
The time to protection and adherence requirements of Truvada and F/TAF for protection from HIV-1 infection
Open Date: 2020-02-01
Close Date: 2022-02-01
Articles (20)
Objectives To describe HIV care outcomes in people of Black ethnicities living in England during the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2; coronavirus disease 2019 [COVID‐19]) pandemic. Methods This was an observational cohort study of people of self‐reported Black ethnicities attending for HIV care at nine HIV clinics across England. The primary outcome was a composite of antiretroviral therapy (ART) interruption and HIV viraemia (HIV RNA ≥200 copies/mL) ascertained via self‐completed questionnaires and review of medical records. We used multivariable logistic regression to explore associations between ART interruption/HIV viraemia and demographic factors, pre‐pandemic HIV immunovirological control, comorbidity status, and COVID‐19 disease and vaccination status. Results We included 2290 people (median age 49.3 years; 56% female; median CD4 cell count 555 cells/mm 3 ; 92% pre‐pandemic HIV RNA <200 copies/mL), of whom 302 (13%) reported one or more ART interruption, 312 (14%) had documented HIV viraemia ≥200 copies/mL, and 401 (18%) experienced the composite endpoint of ART interruption/HIV viraemia. In multivariable analysis, a pre‐pandemic HIV RNA <200 copies/mL (odds ratio [OR] 0.21; 95% confidence interval [CI] 0.15–0.30) and being vaccinated against SARS‐CoV‐2 (OR 0.41; 95% CI 0.30–0.55) were associated with reduced odds of ART interruption/HIV viraemia; pandemic‐related disruptions to HIV care were common self‐reported additional factors. Conclusions During the COVID‐19 pandemic, one in six people of Black ethnicities in this HIV cohort experienced an ART interruption/HIV viraemia. Some of these episodes resulted from pandemic‐related healthcare disruptions. Associations with suboptimal engagement in HIV care pre‐pandemic and not being vaccinated against SARS‐CoV‐2 suggest that wider health beliefs and/or poor healthcare access may have been contributory factors.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Collaborators (19)
Frank A. Post
-
Susanna Dunachie
Professor at University of Oxford
University of Oxford
Félix Gutiérrez
Professor of Medicine
Universidad Miguel Hernández de Elche
Genevieve Elizabeth Martin
University of Melbourne
Holly Middleditch
King's College Hospital
Carolina Herrera
Imperial College London
Jerry Tam
King's College London
Francesca Chiodi
Professor in Host-Parasite Interaction
Karolinska Institutet
Chloe Orkin
-
Jesper Gunst
Aarhus University
Javier Martinez-Picado
Associate professor
-
Ole Søgaard
Professor
Aarhus University
Rikke Olesen
Aarhus University
John Frater
University of Oxford
Paul Denton
Assistant Professor (Tenure Track)
University of Nebraska Omaha
CHRISTINE KATLAMA
-
Maria C. Puertas
AIDS Research Institute Irsicaixa
Michael Malim
King’s College London
Ming Jie Lee
Imperial College London
Make your next move.
Prepare your application
Review drafts before you send them.